|
DE19718012C1
(de)
*
|
1997-04-29 |
1998-10-08 |
Jenapharm Gmbh |
Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
|
|
US6274591B1
(en)
|
1997-11-03 |
2001-08-14 |
Joseph F. Foss |
Use of methylnaltrexone and related compounds
|
|
US20030158220A1
(en)
*
|
1997-11-03 |
2003-08-21 |
Foss Joseph F. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
|
|
US6559158B1
(en)
|
1997-11-03 |
2003-05-06 |
Ur Labs, Inc. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
|
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
|
EP1041988A4
(en)
|
1997-12-22 |
2002-03-13 |
Euro Celtique Sa |
METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
|
|
EP1041987B1
(en)
|
1997-12-22 |
2006-04-19 |
Euro-Celtique S.A. |
Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrexone
|
|
DE19853487A1
(de)
*
|
1998-11-19 |
2000-05-25 |
Fumapharm Ag Muri |
Verwendung von Dialkylfumaraten
|
|
US6451806B2
(en)
|
1999-09-29 |
2002-09-17 |
Adolor Corporation |
Methods and compositions involving opioids and antagonists thereof
|
|
US6469030B2
(en)
|
1999-11-29 |
2002-10-22 |
Adolor Corporation |
Methods for the treatment and prevention of ileus
|
|
US6716449B2
(en)
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
|
EP2092936B1
(en)
|
2000-02-08 |
2013-03-20 |
Euro-Celtique S.A. |
Tamper-resistant oral opioid agonist formulations
|
|
EP1387673B1
(en)
|
2001-05-11 |
2010-12-29 |
Endo Pharmaceuticals Inc. |
Abuse-resistant controlled-release opioid dosage form
|
|
CA2446738C
(en)
*
|
2001-05-11 |
2012-05-29 |
Endo Pharmaceuticals, Inc. |
Abuse-resistant opioid dosage form
|
|
US20030022909A1
(en)
*
|
2001-06-05 |
2003-01-30 |
University Of Chicago |
Use of methylnaltrexone to treat immune suppression
|
|
SI1416842T1
(sl)
|
2001-07-18 |
2009-06-30 |
Euro Celtique Sa |
Farmacevtske kombinacije oksikodona in naloksona
|
|
US20030157168A1
(en)
|
2001-08-06 |
2003-08-21 |
Christopher Breder |
Sequestered antagonist formulations
|
|
IL160222A0
(en)
|
2001-08-06 |
2004-07-25 |
Euro Celtique Sa |
Opioid agonist formulations with releasable and sequestered antagonist
|
|
ES2654819T3
(es)
*
|
2001-10-18 |
2018-02-15 |
Nektar Therapeutics |
Conjugados poliméricos de antagonistas de opioides
|
|
HUE032656T2
(en)
*
|
2002-04-05 |
2017-10-30 |
Euro Celtique Sa |
Pharmaceutical composition containing oxicodone and naloxone
|
|
CN1703200B
(zh)
|
2002-09-20 |
2012-02-29 |
奥尔制药公司 |
隔离亚单元和相关组合物及方法
|
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
|
AU2013203378B2
(en)
*
|
2003-04-08 |
2016-09-15 |
Progenics Pharmaceuticals, Inc. |
Pharmaceutical formulations containing methylnaltrexone
|
|
RU2005134364A
(ru)
*
|
2003-04-08 |
2006-06-10 |
Проджиникс Фармасьютикалз, Инк. (Us) |
Комбинированное лечение запора
|
|
HRP20150037T4
(hr)
*
|
2003-04-08 |
2022-09-02 |
Progenics Pharmaceuticals, Inc. |
Farmaceutske formulacije koje sadrže metilnaltrekson
|
|
MXPA05010819A
(es)
*
|
2003-04-08 |
2006-03-30 |
Progenics Pharm Inc |
Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
|
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
|
US20060182692A1
(en)
|
2003-12-16 |
2006-08-17 |
Fishburn C S |
Chemically modified small molecules
|
|
EP2905033B1
(en)
*
|
2003-12-16 |
2020-09-02 |
Nektar Therapeutics |
Monodisperse PEGylated naloxol compositions
|
|
EP1604667A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the restless leg syndrome
|
|
EP1604666A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
|
AU2006206454A1
(en)
*
|
2005-01-20 |
2006-07-27 |
Progenics Pharmaceuticals, Inc. |
Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
|
|
GEP20105052B
(en)
*
|
2005-01-28 |
2010-07-26 |
Euro Celtique Sa |
Alcohol resistant dosage forms
|
|
EP1702558A1
(en)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
|
EP1695700A1
(en)
*
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Dosage form containing oxycodone and naloxone
|
|
US8524731B2
(en)
|
2005-03-07 |
2013-09-03 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
|
ES2714198T3
(es)
|
2005-03-07 |
2019-05-27 |
Univ Chicago |
Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
|
|
US8518962B2
(en)
|
2005-03-07 |
2013-08-27 |
The University Of Chicago |
Use of opioid antagonists
|
|
US9662325B2
(en)
|
2005-03-07 |
2017-05-30 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
|
AR057035A1
(es)
|
2005-05-25 |
2007-11-14 |
Progenics Pharm Inc |
SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
|
|
AR057325A1
(es)
|
2005-05-25 |
2007-11-28 |
Progenics Pharm Inc |
Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
|
|
US20080194611A1
(en)
*
|
2005-06-03 |
2008-08-14 |
Alverdy John C |
Modulation of Cell Barrier Dysfunction
|
|
DE102006006532B4
(de)
|
2006-02-10 |
2007-11-08 |
Biogenerics Pharma Gmbh |
Pharmazeutische Zubereitung
|
|
SI2719378T1
(sl)
|
2006-06-19 |
2016-11-30 |
Alpharma Pharmaceuticals Llc |
Farmacevtski sestavki
|
|
TWI489984B
(zh)
|
2006-08-04 |
2015-07-01 |
Wyeth Corp |
用於非經腸道傳輸化合物之配方及其用途
|
|
US20080139654A1
(en)
*
|
2006-12-09 |
2008-06-12 |
Eric Mott Soderling |
Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
|
|
CL2008000905A1
(es)
|
2007-03-29 |
2008-08-22 |
Progenics Pharm Inc |
Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena.
|
|
MX2009010550A
(es)
|
2007-03-29 |
2009-12-14 |
Progenics Pharm Inc |
Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
|
|
SI2565195T1
(sl)
|
2007-03-29 |
2015-09-30 |
Wyeth Llc |
Periferalni opioidni receptorji in antagonisti in njih uporaba
|
|
EP2214672B1
(en)
*
|
2007-10-18 |
2012-10-17 |
Aiko Biotechnology |
Combination analgesic employing opioid and neutral antagonist
|
|
US8748448B2
(en)
|
2007-10-18 |
2014-06-10 |
Aiko Biotechnology |
Combination analgesic employing opioid agonist and neutral antagonist
|
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
|
EP2240489A1
(en)
|
2008-02-06 |
2010-10-20 |
Progenics Pharmaceuticals, Inc. |
Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
|
|
EP2278966B1
(en)
|
2008-03-21 |
2019-10-09 |
The University of Chicago |
Treatment with opioid antagonists and mtor inhibitors
|
|
CA2729582C
(en)
|
2008-07-01 |
2017-09-19 |
University Of Chicago |
Particles containing an opioid receptor antagonist and methods of use
|
|
CA2676881C
(en)
*
|
2008-09-30 |
2017-04-25 |
Wyeth |
Peripheral opioid receptor antagonists and uses thereof
|
|
SG174286A1
(en)
|
2009-03-10 |
2011-10-28 |
Euro Celtique Sa |
Immediate release pharmaceutical compositions comprising oxycodone and naloxone
|
|
US9056054B2
(en)
|
2009-06-25 |
2015-06-16 |
Elite Laboratories, Inc. |
Abuse resistant oral dosage forms
|
|
UA123856C2
(uk)
|
2010-03-11 |
2021-06-16 |
Уайт Елелсі |
Фармацевтичні композиції метилналтрексону та натрію додецилсульфату для перорального введення
|
|
CN103002881B
(zh)
|
2010-05-10 |
2015-09-02 |
欧洲凯尔特公司 |
载有活性剂的颗粒与额外活性剂的组合
|
|
AU2011252039B2
(en)
|
2010-05-10 |
2014-06-12 |
Euro-Celtique S.A. |
Pharmaceutical compositions comprising hydromorphone and naloxone
|
|
CA2798884C
(en)
|
2010-05-10 |
2016-09-13 |
Euro-Celtique S.A. |
Manufacturing of active-free granules and tablets comprising the same
|
|
JP2016525138A
(ja)
|
2013-07-23 |
2016-08-22 |
ユーロ−セルティーク エス．エイ． |
疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
|
|
CA3042642A1
(en)
|
2013-08-12 |
2015-02-19 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded immediate release abuse deterrent pill
|
|
WO2015071380A1
(en)
|
2013-11-13 |
2015-05-21 |
Euro-Celtique S.A. |
Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
|
|
WO2015086528A1
(de)
|
2013-12-11 |
2015-06-18 |
Develco Pharma Schweiz Ag |
Naloxon-monopräparat und mehrschichttablette
|
|
US10105360B2
(en)
|
2013-12-11 |
2018-10-23 |
Develco Pharma Schweiz Ag |
Method and composition for the treatment of opioid induced constipation
|
|
US10172797B2
(en)
|
2013-12-17 |
2019-01-08 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
|
US9492444B2
(en)
|
2013-12-17 |
2016-11-15 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
|
CA2955229C
(en)
|
2014-07-17 |
2020-03-10 |
Pharmaceutical Manufacturing Research Services, Inc. |
Immediate release abuse deterrent liquid fill dosage form
|
|
US9132096B1
(en)
|
2014-09-12 |
2015-09-15 |
Alkermes Pharma Ireland Limited |
Abuse resistant pharmaceutical compositions
|
|
WO2016061531A1
(en)
|
2014-10-17 |
2016-04-21 |
Salix Pharmaceuticals, Inc. |
Use of methylnaltrexone to attenuate tumor progression
|
|
WO2016064873A1
(en)
|
2014-10-20 |
2016-04-28 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extended release abuse deterrent liquid fill dosage form
|
|
US20160256452A1
(en)
*
|
2015-03-06 |
2016-09-08 |
Develco Pharma Schweiz Ag |
Composition Of Opioid Receptor Antagonists For Use In Treatment Of Constipation With Highly Increased Whole Gut Transit Time
|
|
US20160256451A1
(en)
|
2015-03-06 |
2016-09-08 |
Develco Pharma Schweiz Ag |
Dosage of naloxone
|
|
WO2016193456A2
(en)
|
2015-06-03 |
2016-12-08 |
Develco Pharma Schweiz Ag |
Opioid receptor antagonist for use in treating patients with severe constipation
|
|
EP3290027A1
(en)
|
2016-09-02 |
2018-03-07 |
Develco Pharma Schweiz AG |
Method and composition for the treatment of opioid induced constipation
|
|
BR112021022194A2
(pt)
|
2019-05-07 |
2021-12-28 |
Bausch Health Ireland Ltd |
Formulações líquidas para dosagem oral de metilnaltrexona
|